Inventiva (NASDAQ:IVA) Shares Up 5.6% – Should You Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price shot up 5.6% during mid-day trading on Tuesday . The company traded as high as $3.70 and last traded at $3.7050. Approximately 870,594 shares traded hands during mid-day trading, an increase of 75% from the average daily volume of 498,498 shares. The stock had previously closed at $3.51.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Truist Financial began coverage on Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 price target on the stock. Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $16.56.

Inventiva Price Performance

The stock has a fifty day moving average price of $4.84 and a 200 day moving average price of $5.36.

Inventiva (NASDAQ:IVA) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million during the quarter. On average, research analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Inventiva

Institutional investors and hedge funds have recently modified their holdings of the company. Creative Planning purchased a new position in Inventiva during the second quarter valued at approximately $32,000. Commonwealth Equity Services LLC lifted its stake in Inventiva by 19.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock worth $361,000 after purchasing an additional 12,704 shares in the last quarter. Virtu Financial LLC bought a new position in Inventiva in the 4th quarter valued at $60,000. XTX Topco Ltd bought a new position in Inventiva in the 4th quarter valued at $84,000. Finally, NewEdge Advisors LLC purchased a new position in shares of Inventiva during the 3rd quarter valued at $116,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.